TickerFacts.

iSpecimen Inc. (ISPC): Capital Expenditures

Annual figures by period end, from SEC filings.

$454
Year ended 2025-12-31
-87.2%
3-year compound annual growth
+1.3%
5-year compound annual growth
$215.5K2020-12-31: $4262021-12-31: $2.5K2022-12-31: $215.5K2023-12-31: $19.5K2024-12-31: $31.5K2025-12-31: $454$454
2020-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$454-98.6%2026-04-01, From 2025-01-01
2024-12-31$31.5K+62.0%2026-04-01, From 2024-01-01
2023-12-31$19.5K-91.0%2025-04-14, From 2023-01-01
2022-12-31$215.5Kn/m2024-03-13, From 2022-01-01
2021-12-31$2.5K+498.6%2023-03-30, From 2021-01-01
2020-12-31$426n/a2022-03-22, From 2020-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
iSpecimen Inc. (ISPC)2025-12-31$454-98.6%
OneMedNet Corp (ONMD)2025-12-31$13.0K-74.5%
Absci Corp (ABSI)2025-12-31$1.11M+174.0%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$60.6K-23.4%
Foxo Technologies Inc. (FOXO)2025-12-31$62.0Kn/a
OmniAb, Inc. (OABI)2025-12-31$565.0K-69.9%
MaxCyte, Inc. (MXCT)2025-12-31$1.77M+7.1%
NRC Health (NRC)2025-12-31$10.71M-30.7%
Medpace Holdings, Inc. (MEDP)2025-12-31$31.36M-14.2%

Compare ISPC, ONMD, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗